As the biopharmaceutical industry evolves from a “one-size-fits-all” approach to more personalized medicine, laboratories are doing the same. Because for today’s life sciences innovators targeting rare diseases and seeking to develop new precision medicines in small quantities, yesterday’s model of large-scale manufacturing centers and global distribution centers no longer works. The same is true for traditional early detection and in vivo research spaces.
“How we approach drug discovery, development, commercialization and delivery must change at every level,” said Brian Taylor, CEO of Boston-based SmartLabs. “Everything we do has to be close to the patient, and that starts with how we build and reconfigure our exam rooms.”
smart labprovides the first integrated platform that combines reconfigurable laboratory infrastructure, operations, and scientific expertise to address some of the biggest challenges facing the biotechnology and life sciences industry: (such as limited access and leaner business models) and are working to accelerate growth. Discovering, developing and delivering breakthrough scientific advances. We spoke with Taylor about opportunities in the biopharmaceutical industry and his vision for the future.
Congratulations on your recent appointment as CEO. Can you tell us more about your background and the industry challenges that brought you to SmartLabs?
Taylor: i went smart lab I’ve been working in the biopharmaceutical/biomanufacturing world for about 3 and a half years now, almost 30 years. I started my career at Genentech, focusing on large-scale monoclonal antibody production processes, before moving to GE. Healthcare Life SciencesThere I was running a global biomanufacturing solutions business. From there, I started focusing more on different treatments. We’re seeing a shift in research and development focus away from monoclonal antibody treatments and large-scale manufacturing, and toward treatments such as cell and gene therapy. I have seen the industry evolve as more companies begin to manufacture small-batch, high-mix product portfolios to treat rare diseases with higher efficacy or fewer patients. Ta. Eventually, that interest led me to his SmartLabs. I am energized by the opportunity to be part of a paradigm-shifting solution that allows programs of all sizes to work together to bring these treatments closer to patients.
SmartLabs supports scientists by providing flexible turnkey lab solutions. Can you explain what that looks like?
Taylor: At a high level, we provide solutions and infrastructure that support scientific progress. I would like to use this analogy. Different cars are needed for different tasks. Therefore, if you want to race on the highway, you will use a sports car. But if he goes to the market to buy 10 bushels of apples, he will pick up the truck. Now, let’s apply that to science. Conducting chemistry research has different types of laboratory needs than biology research. SmartLabs provides a one-base infrastructure that can be adapted and transformed into any lab environment you need. For example, a biology lab we build can be reconfigured into a chemistry lab in about 4-6 weeks.
For example, consider an organization that manufactures antibody-drug conjugates. Developing a monoclonal antibody may require a biology lab, but the drug actually attached to it is probably a chemical, in which case a chemistry lab is required. Companies work with us because we help enable their laboratory transformation. Our team also provides expert guidance and ongoing in-depth operational support.
When you think about the future of healthcare, what do you see? And how are SmartLabs helping to make it happen?
Taylor: I have a dream that one day when a child has lymphoblastic leukemia and is receiving CAR T-cell therapy, the entire process will be at the bedside. After all, it needs their blood and cells to do its job. Wouldn’t it be unbelievable if that happened in a hospital? We believe we can get there, but the path will require rethinking everything. You can’t go from today’s global, central manufacturing to the patient’s bedside in one fell swoop.
SmartLabs can bridge the gap from old ways to new ways of doing things by helping our scientific partners make these incremental changes. For example, a regional CAR T therapy center can be built on a platform like ours that is flexible and adaptable to a variety of manufacturing processes and process development tasks. From there, you can move from regional centers to local hospitals and even closer to the patient’s bedside.
As we look to the future, I think anyone working in the industry today would agree that we need to approach things differently. At the same time, we have made incredible advances in our understanding of disease. For many years we have poisoned the disease and tried to keep it at bay, but today we are talking about curing the disease at its root by programming the human body to fight the disease. Masu.
That being said, I am very excited about the future and how these developments will benefit patients. And, SmartLabs drives meaningful change so that research, development, manufacturing and more support today’s unprecedented diversity and pace of scientific innovation, delivering breakthrough treatments to patients who need them most. We are confident that we will be a reliable partner.
SmartLabs is based on the belief that modern science requires a new, adaptable resource infrastructure as the standard to future-proof the industry and accelerate the pace of scientific progress for everyone, everywhere. was established in 2015. The company offers the first integrated platform that combines flexible laboratory infrastructure, operations, digital solutions and scientific expertise. The company’s Managed Research Centers enable customers to access private, enterprise-grade R&D infrastructure and manufacturing solutions “as a service” with no upfront investment, providing comprehensive support for a variety of modalities across all stages of drug development. We will be able to provide end-to-end life science solutions. cycle. Headquartered in Boston, SmartLabs provides a variety of biotech, biopharmaceutical, and life sciences organizations with unique models designed to enable the future of the industry. For more information, please visit: www.smartlabs.com.
